Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1996;27:85-89

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, K.
Right arrow Articles by Zimmerman, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, K.
Right arrow Articles by Zimmerman, B. G.

(Hypertension. 1996;27:85-89.)
© 1996 American Heart Association, Inc.


Articles

Kinin-Mediated Antihypertensive Effect of Captopril in Deoxycorticosterone Acetate–Salt Hypertension

Ke Chen; Xuewei Zhang; Earl W. Dunham; Ben G. Zimmerman

From the Department of Pharmacology, University of Minnesota, Minneapolis.

Correspondence to Ben G. Zimmerman, 3-249 Millard Hall, University of Minnesota, 435 Delaware St SE, Minneapolis, MN 55455.

Abstract On the basis of evidence suggesting the activation of the kallikrein-kinin system in steroid-induced hypertension, we considered the possibility that the angiotensin-converting enzyme inhibitor captopril would lower the arterial blood pressure in deoxycorticosterone acetate (DOCA)–salt hypertensive rats through kininase II inhibition. In conscious DOCA-salt hypertensive rats with intact kidneys (n=6) or uninephrectomized rats (n=5), the short-term administration of captopril (8 mg/kg IV) decreased mean blood pressure from 141±3 to 118±3 mm Hg (P<.05) and from 176±12 to 158±15 mm Hg (P<.05), respectively. The maximal effect of captopril was manifested between 40 and 50 minutes after its administration, and blood pressure remained depressed for at least 2 hours. The bradykinin B2 receptor antagonist Hoe 140 (500 µg/kg IV) abolished the antihypertensive effect of captopril in the DOCA-salt hypertensive rats, indicating kinin involvement. Losartan, an angiotensin type 1 receptor antagonist, had no effect on blood pressure in another group of DOCA-salt hypertensive rats (n=9) and did not significantly change the response to captopril. No effect of the angiotensin-converting enzyme inhibitor was seen in normotensive control rats (n=5), indicating the absence of a nonspecific hypotensive action of the drug. Plasma renin activity was lower in the DOCA-salt hypertensive rats (0.7±0.2 ng angiotensin I/mL per hour, n=4) than in normotensive control rats (8.8±1.7, n=4). The involvement of kinins in the antihypertensive effect of captopril in DOCA-salt hypertension supports the contention that the kallikrein-kinin system contributes to blood pressure regulation in this hypertension model.


Key Words: desoxycorticosterone • captopril • rats, inbred strains • kallikrein-kinin system




This article has been cited by other articles:


Home page
HypertensionHome page
H. Peng, O. A. Carretero, T.-D. Liao, E. L. Peterson, and N.-E. Rhaleb
Role of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline in the Antifibrotic and Anti-Inflammatory Effects of the Angiotensin-Converting Enzyme Inhibitor Captopril in Hypertension
Hypertension, March 1, 2007; 49(3): 695 - 703.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. C. DE GRACIA, A. OSUNA, F. O'VALLE, R. G. DEL MORAL, R. WANGENSTEEN, C. G. DEL RIO, and F. VARGAS
Deoxycorticosterone Suppresses the Effects of Losartan in Nitric Oxide--Deficient Hypertensive Rats
J. Am. Soc. Nephrol., November 1, 2000; 11(11): 1995 - 2000.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. A. Katz, J. A. Opsahl, S. E. Wernsing, L. M. Forbis, J. Smith, and L. J. Heller
Myocardial renin is neither necessary nor sufficient to initiate or maintain ventricular hypertrophy
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2000; 278(3): R578 - R586.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
N.-E. Rhaleb, H. Peng, M. E. Alfie, E. G. Shesely, and O. A. Carretero
Effect of ACE Inhibitor on DOCA-Salt– and Aortic Coarctation–Induced Hypertension in Mice : Do Kinin B2 Receptors Play a Role?
Hypertension, January 1, 1999; 33(1): 329 - 334.
[Abstract] [Full Text] [PDF]